FDA Approves mTOR Inhibitor Everolimus for Breast Cancer
Ob.Gyn. News Digital Network
The approval of everolimus has been expanded to include a group of postmenopausal women with advanced hormone receptor–positive, HER2-negative breast cancer, the Food and Drug Administration announced on July 20. A mammalian target of ...
FDA approves Novartis drug Afinitor for breast cancer
Novartis gains FDA approval for Afinitor® in advanced breast cancer marking a ...
FDA approves Afinitor for advanced breast cancer